Ironwood Pharmaceuticals, Inc.
IRWD
$4.31
$0.235.64%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 389.32M | 361.51M | 296.15M | 338.99M | 308.52M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 389.32M | 361.51M | 296.15M | 338.99M | 308.52M |
| Cost of Revenue | 88.69M | 89.64M | 95.14M | 98.66M | 106.02M |
| Gross Profit | 300.62M | 271.87M | 201.02M | 240.32M | 202.50M |
| SG&A Expenses | 64.35M | 69.84M | 82.06M | 95.91M | 110.12M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 153.05M | 159.48M | 177.20M | 194.58M | 216.14M |
| Operating Income | 236.27M | 202.03M | 118.95M | 144.41M | 92.38M |
| Income Before Tax | 207.38M | 171.47M | 70.03M | 93.57M | 42.91M |
| Income Tax Expenses | 77.51M | 69.29M | 46.01M | 65.02M | 50.80M |
| Earnings from Continuing Operations | 129.87 | 102.18 | 24.02 | 28.55 | -7.89 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 129.87M | 102.18M | 24.02M | 28.55M | -7.89M |
| EBIT | 236.27M | 202.03M | 118.95M | 144.41M | 92.38M |
| EBITDA | 238.11M | 203.88M | 120.83M | 146.32M | 94.32M |
| EPS Basic | 0.79 | 0.63 | 0.15 | 0.17 | -0.05 |
| Normalized Basic EPS | 0.80 | 0.67 | 0.35 | 0.44 | 0.24 |
| EPS Diluted | 0.76 | 0.58 | 0.11 | 0.15 | -0.06 |
| Normalized Diluted EPS | 0.77 | 0.62 | 0.31 | 0.40 | 0.23 |
| Average Basic Shares Outstanding | 652.51M | 649.83M | 647.35M | 644.81M | 642.30M |
| Average Diluted Shares Outstanding | 674.07M | 683.73M | 678.01M | 675.99M | 658.46M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |